Trials / Completed
CompletedNCT02334930
Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 13 (actual)
- Sponsor
- University Hospital, Bordeaux · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
PEComa is rare tumor affecting particularly patients with Tuberous Sclerosis. Biological similarities were seen between PEComa and infantile hemangioma. Propranolol is highly efficient to treat infantile hemangioma and we believe that this drug can also be useful for the treatment of PEComa. Purpose : to understand the mechanism of action of propranolol in PEComas and related pediatric vascular lesions and to select possible novel targets of betablockers in vascular tumors related to PEComas by using YAP oncogene activation as a molecular marker
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Biopsy |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2015-01-08
- Last updated
- 2016-08-22
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02334930. Inclusion in this directory is not an endorsement.